The CEO of FibroBiologics describes the idea of using fibroblasts rather than stem cells for regenerative medicine and chronic diseases
Pete O'Heeron makes the case for fibroblasts and describes FibroBiologics's clincal MS program and upcoming ones for diabetic wound care and degenerative disc disease.